The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial

Sci Rep. 2024 Jan 11;14(1):1053. doi: 10.1038/s41598-024-51726-z.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a metabolic dysfunction of the liver defined as an abnormal accumulation of fat within the liver without secondary triggers like alcohol consumption or viral hepatitis. Piperine, the bio-active ingredient of black pepper, can exert a significant function in treatment of individuals with NAFLDand early cirrhosis. We investigated the impact of piperine consumption with a duration of 12 weeks on patients with NAFLD and early cirrhosis compared toplacebo consumption. In a double-blind study, patients with NAFLD and early stage of cirrhosis were haphazardly distributed into case and control groups. They were prescribed a placebo and 5 mg of piperine for 12 weeks, respectively. The demographic and laboratory parameters of individuals were assessed as the baseline and after the duration of piperine intake. Piperine with a daily dosage of 5 mg could significantly decrease hepatic enzymes and glucose, and alleviate dyslipidemia in the case arm rather than the control arm. Moreover, HOMA levels and insulin resistance were reduced in case participants compared to the control counterparts. In the absence of approved medicinal intervention for patients with NAFLD, and regarding the favorable impact of piperine on NAFLD more studies on this subject are warranted.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Alkaloids*
  • Benzodioxoles*
  • Double-Blind Method
  • Humans
  • Liver Cirrhosis / drug therapy
  • Metabolic Diseases*
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Piperidines*
  • Polyunsaturated Alkamides*

Substances

  • piperine
  • Alkaloids
  • Piperidines
  • Benzodioxoles
  • Polyunsaturated Alkamides